GLP-1 Medications Show Medical Cost Benefits, With Adherence and Women’s Health as Key Factors
Despite higher overall treatment costs, diabetes and weight loss patients on second-generation GLP-1 medications experience meaningfully slower medical cost growth compared to matched non-users—though maximizing this benefit hinges heavily on therapy adherence, according to a comprehensive new analysis by Aon.
“Conditions like obesity, diabetes and cancer are among the most pressing health challenges facing employees, their families and the organizations that support them,” said Lisa Stevens, chief administrative officer of Aon. “Our research demonstrates the power of GLP-1 therapies to transform health outcomes, with especially promising results for women — including substantial reductions in cancer and heart risks.
Steady Progress on Medical Costs, With Adherence as the Linchpin
The Aon analysis, which examined deidentified commercial claims from approximately 50 million lives, found that users of medications like Mounjaro, Ozempic, Wegovy and Zepbound saw medical spending trajectories that diverged favorably from control groups as treatment progressed. Diabetes patients using GLP-1s demonstrated a six percentage point improvement in medical cost growth relative to non-users over 12 to 30 months, while weight loss users showed three percentage point improvements over an 12 to 18-month window.
However, the data underscores a critical reality: users maintaining at least 80% adherence to therapy nearly doubled these gains. Highly adherent diabetes patients achieved a nine percentage point improvement in medical spend growth, while compliant weight loss users reached a seven percentage point improvement. This pattern suggests that sustained engagement with therapy is essential for employers to realize the clinical and economic benefits GLP-1s promise, Aon said.
Unexpected Benefits for Women, New Concerns for Plan Designers
The Aon study surfaced noteworthy gender disparities in both benefits and risks, presenting a complex landscape for employer decision-making.
Female users of GLP-1s—who represented 63% of the study population—experienced substantially larger reductions in hospitalizations due to major adverse cardiovascular events (MACE) than male users: a 47% reduction for women versus a 26% decrease for men, respectively. Beyond cardiovascular outcomes, women showed meaningful protective effects, including approximately 50% lower rates of ovarian cancer incidence, 14% lower breast cancer incidence and 16% reductions in osteoporosis compared to female non-users.
These findings suggest GLP-1 therapy may offer health advantages extending beyond weight management and glucose control. Women also experienced lower hospitalization rates for alcohol or drug abuse, bariatric surgery and certain pancreatic disorders relative to female non-users—reductions that were relatively greater than those observed in men, the report said.
Yet the Aon analysis revealed a countervailing trend: female GLP-1 users experienced higher rates of hospitalization for gallbladder surgery than male counterparts. This finding introduces a potential safety consideration employers may need to weigh when evaluating coverage strategies.
Pricing Pressures and the Case for Coverage Recalibration
Total spending for GLP-1 users continues to exceed that of non-users when accounting for medication costs, a reality that has long complicated employer coverage decisions, according to the report.
However, Aon’s research suggests that viewing GLP-1 coverage through a purely short-term drug expense lens misses the longer-term medical benefit picture. As direct-to-consumer pricing programs expand, newly approved oral formulations enter the market and alternative payment models emerge, drug costs are expected to compress materially, potentially reshaping the cost-benefit equation, the report noted.
Obtain the full report here. &

